Incorrect password
evipedia.ai Suggest Edit

Sulforaphane for Health & Longevity

Evidence Review created on 04/25/2026 using AI4L / Opus 4.7

Also known as: SFN, 1-isothiocyanato-4-(methylsulfinyl)butane, Broccoli Sprout Isothiocyanate

Motivation

Sulforaphane is a sulfur-containing plant compound found most abundantly in young broccoli sprouts and other cruciferous vegetables. It activates the body’s own internal defense system, prompting cells to make more of their own antioxidant, detoxification, and anti-inflammatory protections — a mechanism that has drawn growing interest from longevity, cancer-prevention, and cardiometabolic researchers alike.

The compound was first isolated at Johns Hopkins in 1992 and has since been investigated mainly for cancer chemoprevention and cardiometabolic protection, with additional work in neurodevelopmental and psychiatric conditions. Bioavailability is highly variable: fresh sprouts deliver substantially more circulating sulforaphane than supplements or fully cooked broccoli, and gut microbiome composition further influences how much is actually absorbed.

This review examines the evidence for sulforaphane as a longevity-oriented intervention — what it is, the human and preclinical data on its proposed benefits, the practical risks, the bioavailability problem that shapes every dosing decision, and the protocols used by experienced practitioners and researchers in clinical and longevity settings.

Benefits - Risks - Protocol - Conclusion

This section lists high-level overviews and expert commentary on sulforaphane suitable for orientation before reading the rest of the document.

  • Sulforaphane - Rhonda Patrick

    A continuously updated topic page covering sulforaphane chemistry, bioavailability, Nrf2 activation, individual response variability, and disease-specific evidence. Patrick is widely considered the most prolific science communicator on this compound.

  • The Powerful Health Benefits of Sulforaphane - Chris Kresser

    A Revolution Health Radio episode and accompanying article framing sulforaphane primarily as a detoxification tool, with practical guidance on dietary sources, sprouting, and supplementation.

  • Optimize the Benefits of Broccoli - Richard Waterman

    A consumer-focused overview emphasizing the bioavailability problem (cooking destroys myrosinase) and explaining why glucoraphanin paired with active myrosinase produces meaningfully higher plasma sulforaphane than glucoraphanin alone.

  • Sulforaphane: Its “Coming of Age” as a Clinically Relevant Nutraceutical in the Prevention and Treatment of Chronic Disease - Houghton, 2019

    A narrative review summarizing the translational arc from mechanistic discovery to early human trials in cancer, cardiovascular disease, neurological conditions, and metabolic dysfunction.

  • Broccoli or Sulforaphane: Is It the Source or Dose That Matters? - Yagishita et al., 2019

    A narrative review from the original Talalay-lineage Johns Hopkins group comparing whole-broccoli, sprout, and supplement preparations and dissecting how preparation method governs bioavailability.

Note: No dedicated long-form content on sulforaphane was identified from Peter Attia or Andrew Huberman; both have referenced the compound only briefly within broader micronutrient or longevity discussions.

Grokipedia

  • Sulforaphane

    A reference-style page covering chemical structure, biosynthesis from glucoraphanin via myrosinase, food sources, Nrf2-mediated mechanisms, and overviews of cancer, cardiovascular, neurological, and metabolic research.

Examine

  • Sulforaphane

    Examine’s structured supplement page summarizes effects on inflammation, cellular detoxification, and antioxidant signaling, with grades for individual claims and references to underlying human and animal studies.

ConsumerLab

No dedicated ConsumerLab.com review or product-testing page for sulforaphane or broccoli sprout extract supplements exists as of 04/25/2026.

Systematic Reviews

The following systematic reviews and meta-analyses were identified on PubMed as the most relevant for this intervention.

Mechanism of Action

Sulforaphane exerts its effects primarily by binding cysteine residues on the protein Keap1 (Kelch-like ECH-associated protein 1). Under normal conditions, Keap1 keeps the transcription factor Nrf2 (nuclear factor erythroid 2-related factor 2 — a master regulator of antioxidant and detoxification gene expression) tagged for destruction. When sulforaphane modifies Keap1, Nrf2 escapes degradation and migrates into the cell nucleus. There it switches on more than 200 cytoprotective genes, including:

  • Phase II detoxification enzymes: glutathione S-transferases, NQO1 (NAD(P)H quinone oxidoreductase 1 — converts toxins into safer, water-soluble forms), and UDP-glucuronosyltransferases
  • Antioxidant systems: heme oxygenase-1 (HO-1), glutathione synthesis enzymes, thioredoxin
  • Anti-inflammatory effects: suppression of NF-κB (nuclear factor kappa B — a primary driver of inflammatory gene transcription), reducing TNF-α (tumor necrosis factor alpha — a pro-inflammatory cytokine) and IL-6 (interleukin 6 — a cytokine that drives systemic inflammation)

Secondary mechanisms include inhibition of histone deacetylases (HDACs — enzymes that silence genes by tightening DNA packaging), modulation of DNA methylation, induction of apoptosis in damaged or precancerous cells, and inhibition of phase I cytochrome enzymes that activate procarcinogens.

Competing mechanistic interpretations exist. Critics note that very high concentrations achievable in cell culture do not match plasma concentrations after oral dosing, and argue that some reported in-vitro effects are unlikely to occur at physiologic exposure in humans. Defenders point to Nrf2 activation in human peripheral blood and target tissues at achievable doses as evidence the mechanism translates.

Pharmacological properties:

  • Half-life: Plasma half-life is approximately 1.8 to 2.0 hours after oral dosing; total residence in tissues is longer due to slow turnover of Nrf2-induced enzymes (24–72 hours)
  • Selectivity: Modifies multiple cysteine-rich sensor proteins; Keap1 is the primary recognized target but HDACs and STAT3 (signal transducer and activator of transcription 3 — a transcription factor that drives inflammatory and proliferative gene expression) are also affected
  • Tissue distribution: Lipophilic and crosses the blood-brain barrier; detected in prostate, breast, lung, and brain tissue after oral dosing
  • Metabolism: Conjugated with glutathione via GSTs (CYP enzymes are not the primary route); excreted in urine as N-acetylcysteine and cysteine conjugates (mercapturic acid pathway)

Historical Context & Evolution

Sulforaphane was isolated and identified in 1992 by Paul Talalay’s group at Johns Hopkins, who were screening cruciferous vegetable extracts for compounds capable of inducing phase II detoxification enzymes. The discovery built on earlier epidemiological observations that high consumption of cruciferous vegetables was associated with reduced cancer incidence — observations that had circulated in the nutrition literature for decades but lacked a clear molecular explanation.

The field expanded substantially after the 1997 Talalay paper showing that 3-day-old broccoli sprouts contained 20–50 times more glucoraphanin per gram than mature broccoli. This finding launched both the modern broccoli sprout industry and a research program investigating sulforaphane in cancer chemoprevention, cardiovascular protection, neurological disorders, and environmental toxin defense.

Early enthusiasm produced strong preclinical data across multiple disease models. Translation to controlled human trials has been slower and more variable, partly because of dosing uncertainty (glucoraphanin vs. preformed sulforaphane, with or without active myrosinase) and partly because Nrf2 activation produces broad biological effects that are difficult to capture with single endpoints. Notable randomized trials in autism (Singh et al., 2014, with conflicting follow-up replications), schizophrenia, lung cancer chemoprevention in former smokers, and chronic kidney disease have produced a mixed record — improvements in some biomarkers and outcomes, null results in others.

Scientific opinion has neither dismissed nor fully embraced the compound. Mainstream nutrition guidance recommends cruciferous vegetable intake as a category but does not single out sulforaphane. The longevity and integrative-medicine communities treat it as one of the better-supported phytochemical interventions, while academic skeptics emphasize the gap between mechanistic plausibility and consistent clinical benefit. New evidence on each side continues to emerge.

Expected Benefits

A dedicated search for sulforaphane’s full benefit profile was performed across PubMed, clinical trial registries, foundmyfitness.com, examine.com, and the Life Extension archive before drafting this section.

High 🟩 🟩 🟩

Activation of Phase II Detoxification

Sulforaphane reliably and substantially upregulates phase II detoxification enzymes (GSTs, NQO1, HO-1) in humans. This has been demonstrated in randomized human trials measuring urinary excretion of conjugates of airborne pollutants and dietary carcinogens. The Qidong, China trial (2014) showed approximately 60% greater excretion of acrolein and benzene metabolites in adults consuming broccoli sprout beverages versus placebo. The benefit is mechanism-level rather than disease-level but is the most consistently reproducible human effect.

Magnitude: ~60% increase in urinary excretion of benzene-derived mercapturic acid; 23% increase for acrolein-derived metabolites in heavily polluted populations.

Improved Lipid Profile in Preclinical Models with Emerging Human Signal

Preclinical meta-analysis (Du et al., 2021) shows large, consistent reductions in total cholesterol, LDL-C, and triglycerides across rodent studies. Human evidence is more limited but increasingly supportive: the 2025 schizophrenia meta-analysis (Kassar et al.) reported significant reductions in LDL, triglycerides, and total cholesterol in adjunctive sulforaphane arms, and small human trials in metabolic syndrome have shown comparable effects. The mechanism is plausibly Nrf2-mediated regulation of hepatic lipid metabolism.

Magnitude: Preclinical pooled effect: total cholesterol −15.6 mg/dL, LDL-C −8.4 mg/dL, triglycerides −40.9 mg/dL. Human effect sizes are smaller and not yet well quantified.

Medium 🟩 🟩

Reduction in Behavioral Symptoms in Autism Spectrum Disorder ⚠️ Conflicted

The 2014 Singh et al. RCT in young men with autism reported substantial improvements on standardized behavior scales after 18 weeks of daily sulforaphane. Subsequent trials have been heterogeneous: a 2023 Czech pediatric RCT (Magner et al.) found no significant improvement, while a 2025 meta-analysis (Guo et al.) pooling multiple trials reported significant improvements in irritability and hyperactivity subscales. The conflicted record likely reflects differences in age, baseline severity, formulation, and dose. Evidence is conflicted because adult and adolescent studies tend to show benefit while younger pediatric studies do not.

Magnitude: In responders, ~30–50% reduction in Aberrant Behavior Checklist subscale scores at the population mean.

Modest Improvement in Negative Symptoms of Schizophrenia

The 2025 Kassar et al. meta-analysis of four RCTs reported a modest but statistically significant reduction in negative symptoms (mean difference −1.06 on PANSS (Positive and Negative Syndrome Scale — a standardized rating scale for symptom severity in schizophrenia) negative subscale at 12 weeks) and general psychopathology scores in adults receiving sulforaphane adjunctive to antipsychotics, alongside metabolic improvements. The benefit was not maintained at the longest follow-up (24 weeks), suggesting either escape from effect or sample size limitations.

Magnitude: −1.06 points on PANSS negative subscale (12-week pooled mean difference); modest in absolute terms.

Anti-Inflammatory Biomarker Reduction

Multiple human trials in healthy and metabolically compromised adults have shown reductions in C-reactive protein (CRP — a general marker of systemic inflammation) and inflammatory cytokines after sulforaphane administration. A 2018 randomized study in overweight adults showed CRP reductions of ~20% over 10 weeks. Effects appear dose-dependent and tied to Nrf2 activation magnitude.

Magnitude: ~15–25% reductions in hs-CRP across small human trials; reductions in IL-6 and TNF-α reported in subsets.

Reduction of Pre-cancer Biomarkers (Lung Tissue)

The 2025 Yuan et al. randomized phase II trial in former smokers found that 12 months of oral sulforaphane reduced the Ki-67 proliferation index (Ki-67 — a nuclear protein marker used to gauge how rapidly cells are dividing in a tissue sample) in bronchial biopsies by 20% versus a 65% increase in placebo (p = 0.014). Higher plasma sulforaphane correlated with greater Ki-67 reduction. This is a tissue-level surrogate biomarker rather than a disease endpoint, but is among the strongest direct human cancer-relevant biomarker effects reported.

Magnitude: 20% decrease in Ki-67 vs. 65% increase in placebo over 12 months; ~85 percentage-point relative difference.

Low 🟩

Improved Cognitive Performance and Memory

A small body of human trials, including several from the Life Extension review base, suggests improvements in processing speed and working memory in older adults receiving glucoraphanin-myrosinase preparations over 8–12 weeks. Effects are modest and the evidence base is small, with most studies in Japanese adults using a specific patented formulation. Mechanism is presumed brain Nrf2 activation and reduction of neuroinflammation.

Magnitude: Not quantified in available studies.

Glycemic Control in Type 2 Diabetes

A 2017 Axelsson trial in Swedish adults with poorly controlled type 2 diabetes showed reductions in fasting glucose and HbA1c (a 3-month average blood-sugar marker) at high concentrated broccoli-sprout extract doses. Subsequent replications have been mixed. Effect appears most pronounced in obese patients and at high doses (~150 μmol/day glucoraphanin equivalents).

Magnitude: ~10% reduction in fasting glucose; HbA1c reductions of 0.1–0.3% in responder subgroups.

Renal Protection

A systematic review and meta-analysis (Monteiro et al., 2023) summarized 25 preclinical kidney studies showing consistent improvements in creatinine clearance, proteinuria, and histological kidney injury with sulforaphane. Human trials in chronic kidney disease are ongoing (NCT05797506, NCT04608903). The translational case is encouraging but human outcome data are not yet sufficient to grade higher.

Magnitude: Preclinical pooled SMD (standardized mean difference — a unit-free effect-size measure used in meta-analysis) +1.88 for creatinine clearance, −1.24 for plasma creatinine (vs. controls). Human magnitude undetermined.

Speculative 🟨

Lifespan or Healthspan Extension

No human data demonstrate effects on lifespan or composite healthspan endpoints. Indirect arguments rest on mechanistic similarity to interventions (caloric restriction, exercise) that activate Nrf2, plus rodent studies suggesting protection against age-associated cardiac dysfunction. The Texas Tech “Prevention of Age-associated Cardiac and Vascular Dysfunction Using Avmacol ES” trial (NCT05408559) is currently testing this hypothesis (note: Avmacol is a commercial product manufactured by Nutramax Laboratories, which has a direct financial interest in study outcomes; this same conflict applies to other Avmacol/Nutramax-sponsored trials and to Prostaphane, both cited later in this review). Basis is mechanistic and animal-model only at present.

Neuroprotection Against Alzheimer’s Disease

Strong rodent data show reduction in amyloid plaques and improvements in cognitive function in mouse models. No randomized controlled trial has tested sulforaphane in humans with Alzheimer’s disease or mild cognitive impairment as a primary indication. Basis is currently preclinical and mechanistic only.

Reduction of Microplastic and Endocrine-Disruptor Body Burden

Mechanistic plausibility based on Nrf2-mediated phase II conjugation of bisphenol A (BPA) and phthalate metabolites; observed in vitro but not yet demonstrated in controlled human studies of body burden reduction.

Benefit-Modifying Factors

  • GSTM1 / GSTT1 null genotype: GSTM1 (glutathione S-transferase mu 1) and GSTT1 (glutathione S-transferase theta 1) are genes encoding detoxifying enzymes that conjugate sulforaphane and other isothiocyanates with glutathione for excretion. Approximately 20–50% of populations carry homozygous deletions of GSTM1 or GSTT1. Carriers eliminate sulforaphane more slowly, yielding higher and more sustained plasma levels — paradoxically associated with both greater Nrf2 induction and faster excretion of certain compounds. This polymorphism may explain part of the inter-individual response variability.

  • Gut microbiome composition: Individuals harboring myrosinase-active gut bacteria (certain Lactobacillus and Bacteroides species) can produce sulforaphane from glucoraphanin even when dietary myrosinase is absent (e.g., from cooked broccoli). Microbiome variation likely accounts for substantial inter-individual differences in sulforaphane bioavailability from cooked or supplement-only sources.

  • Baseline oxidative stress and inflammation: Larger Nrf2-induction responses are typically observed in people with elevated baseline oxidative stress markers (e.g., obese, smokers, chronic disease populations), suggesting greater absolute benefit in those starting from higher inflammatory baselines.

  • Sex-based differences: Limited evidence suggests possible differences in metabolism and tissue distribution. A 2025 review (Klepacka et al.) summarized sex-specific effects on hormone-sensitive tissues, with potentially greater estrogen-receptor modulation in women. Most clinical trials have been mixed-sex with insufficient power to detect sex effects.

  • Age: Older adults may show smaller acute Nrf2 induction (declining transcription factor responsiveness with age) but may also have greater room for improvement given higher baseline oxidative stress. The age-related cardiac trial (NCT05408559) is enrolling adults 50+ specifically to test this.

  • Pre-existing thyroid status: People with iodine deficiency or hypothyroidism may have additional sensitivity to high-dose sulforaphane and other isothiocyanates due to potential goitrogenic effects on iodine uptake; baseline thyroid biomarkers can predict tolerability.

Potential Risks & Side Effects

A dedicated search for the full risk and side-effect profile was performed across PubMed, FDA adverse event reporting, drugs.com, examine.com, and major drug references before drafting this section.

High 🟥 🟥 🟥

Gastrointestinal Discomfort

The most common reported adverse effect across human trials, occurring in approximately 10–25% of participants in randomized trials. Includes flatulence, mild abdominal discomfort, loose stools, and nausea. Generally mild, dose-related, and resolves with continued use or dose reduction. Mechanism likely reflects sulfur-compound fermentation in the colon and Nrf2-induced changes to gut barrier and microbiome.

Magnitude: 10–25% incidence in trials at therapeutic doses (50–100 μmol/day); rates higher with raw broccoli sprouts than with capsules.

Medium 🟥 🟥

Goitrogenic Potential / Thyroid Interference

Cruciferous vegetables and the broader isothiocyanate class can interfere with iodide uptake by the thyroid gland, theoretically reducing thyroid hormone production in iodine-deficient individuals. Effect is modest at typical sulforaphane doses but plausible at high chronic intake (e.g., daily broccoli sprout consumption in iodine-deficient populations). Iodine-replete individuals appear largely unaffected. Reported by Rhonda Patrick and others as the chief practical concern for chronic high-dose use.

Magnitude: Not quantified in available studies.

Low 🟥

Allergic Reaction

Rare hypersensitivity reactions to broccoli, broccoli sprouts, or isolated isothiocyanates have been reported in case reports — including contact dermatitis and, very rarely, anaphylactic reactions. Patients with known cruciferous vegetable allergy should avoid concentrated forms.

Magnitude: Not quantified in available studies.

Drug-Metabolism Interactions

Sulforaphane modestly modulates phase I cytochrome P450 enzymes (predominantly inhibition of CYP2A6 — a liver enzyme that metabolizes nicotine, coumarin, and certain procarcinogens — and induction of certain phase II conjugation enzymes), with theoretical implications for drugs metabolized through these pathways. Magnitude in humans is small at typical doses but warrants attention in narrow-therapeutic-window medications.

Magnitude: Not quantified in available studies.

Foodborne Illness from Raw Sprouts

Raw broccoli sprouts grown at home or commercially have been implicated in Salmonella, E. coli, and Listeria outbreaks due to the warm, moist sprouting conditions favoring bacterial growth. This is a hazard of the food source, not the molecule itself, but is the dominant safety concern with home sprouting. Affects pregnant women, immunocompromised individuals, young children, and older adults disproportionately.

Magnitude: Not quantified in available studies.

Speculative 🟨

Bladder Urothelial Effects at Very High Doses

Isolated high-dose preclinical studies have shown urothelial irritation in rodents at sulforaphane exposures far above human therapeutic doses. No human reports at typical intake levels. Basis is preclinical only.

Pro-oxidant Effects at Supraphysiologic Doses

Cell culture data suggest sulforaphane can shift from antioxidant to pro-oxidant behavior at very high concentrations, potentially inducing oxidative stress rather than reducing it. Whether this is achievable through oral dosing in humans is unclear; basis is in-vitro only.

Risk-Modifying Factors

  • GSTM1 / GSTT1 null genotype: Carriers may have higher peak plasma concentrations and slightly increased risk of dose-dependent gastrointestinal effects, though overall adverse event profile remains favorable.

  • Iodine status: Iodine-deficient individuals are at elevated risk of goitrogenic effects from chronic high-dose sulforaphane. Baseline urinary iodine measurement and adequate dietary iodine reduce this risk substantially.

  • Sex-based differences: No clinically established differences in adverse event profile between men and women; potential pregnancy-specific cautions reflect concerns about raw sprout consumption (foodborne illness) rather than sulforaphane itself.

  • Pre-existing hypothyroidism: Should be monitored more carefully when initiating chronic high-dose sulforaphane; existing thyroid hormone replacement may need dose review if biomarkers shift.

  • Pre-existing cruciferous allergy: Absolute contraindication for concentrated sulforaphane preparations.

  • Age and immune status: Pregnant women, older adults, young children, and immunocompromised individuals face higher consequences from raw-sprout-associated foodborne illness; pasteurized supplements eliminate this concern.

  • Inflammatory bowel disease: Some practitioners report symptom exacerbation at high doses in active IBD; mechanism is unclear and signal is anecdotal.

Key Interactions & Contraindications

  • Anticoagulants and antiplatelet drugs (warfarin, clopidogrel, aspirin): Caution. Sulforaphane has weak antiplatelet activity in vitro; clinical bleeding risk at typical doses is low but additive effects are theoretically possible. Monitor INR (international normalized ratio — a measure of clotting time) when introducing high doses to warfarin-stabilized patients.

  • Levothyroxine and thyroid hormone replacement: Caution. Chronic high-dose sulforaphane combined with iodine-deficient diet may necessitate thyroid hormone dose adjustment. Re-test TSH (thyroid stimulating hormone — pituitary hormone used to assess thyroid function) 6–12 weeks after starting chronic high-dose use.

  • Drugs metabolized by CYP2A6 (e.g., nicotine, coumarin): Caution. Sulforaphane modestly inhibits CYP2A6; clinical relevance is small but worth noting in pharmacogenetically sensitive patients.

  • Acetaminophen: Theoretical hepatoprotective interaction (Nrf2-mediated glutathione regeneration). Not contraindicated; possibly favorable.

  • Antihyperglycemic agents (metformin, SGLT2 inhibitors — sodium-glucose cotransporter 2 inhibitors that lower blood sugar via urinary glucose excretion): Caution. Additive blood-glucose-lowering effects possible at higher sulforaphane doses; monitor in well-controlled diabetics.

  • Lipid-lowering supplements (red yeast rice, berberine, niacin): Additive effect. May produce greater LDL-C and triglyceride reductions than either alone; monitor lipid panel.

  • NAC (N-acetylcysteine) and other glutathione precursors: Additive Nrf2-related effects; no contraindication but redundant pathway activation may yield diminishing returns.

  • Iodine supplements: Mitigating interaction. Adequate iodine intake offsets the goitrogenic potential of chronic sulforaphane use.

  • Doxorubicin and other anthracycline chemotherapies: Active investigation (NCT03934905). Preclinical data suggest cardioprotection without compromising antitumor efficacy; clinical guidance pending.

  • Populations who should avoid: Individuals with known cruciferous vegetable allergy (absolute contraindication), individuals with severe iodine deficiency without correction, and pregnant women using raw sprouts (food safety concern, not molecular concern). Individuals on warfarin with INR > 3.5, recent gastrointestinal surgery, or severe IBD flare warrant case-by-case caution.

Risk Mitigation Strategies

  • Use pasteurized or lab-tested sprouts to avoid foodborne illness: Commercial sprouts subjected to pasteurization or supplements made from heat-treated extract eliminate the Salmonella/E. coli/Listeria risk associated with home-grown raw sprouts. Particularly important for pregnant women, immunocompromised individuals, and those over 65.

  • Confirm baseline iodine sufficiency before chronic high-dose use: Test urinary iodine or thyroid panel (TSH, free T4) before initiating daily high-dose sulforaphane; supplement dietary iodine (e.g., 150 μg/day from food or multivitamin) if borderline. This mitigates the goitrogenic risk identified above.

  • Start low and titrate to reduce gastrointestinal side effects: Begin at ~10–25 μmol/day (one-quarter to half the typical therapeutic dose) for 1–2 weeks, then escalate by similar increments every 1–2 weeks to target dose. This mitigates the dose-related GI discomfort that affects 10–25% of users.

  • Take with food to improve tolerability: Consuming sulforaphane or sprouts with a meal reduces gastric discomfort and may improve absorption of lipophilic forms.

  • Monitor INR within 2–4 weeks of initiation in warfarin-stabilized patients: Mitigates the small but theoretical bleeding risk from drug-supplement interaction.

  • Recheck TSH at 6–12 weeks of chronic high-dose use: Detects sub-clinical thyroid shifts before they progress; particularly relevant for those with prior hypothyroidism or borderline iodine status.

  • Choose products with documented myrosinase activity or pre-formed sulforaphane: Mitigates the substantial bioavailability variability of glucoraphanin-only supplements; reduces wasted dose and inconsistent response.

  • Hold or reduce dose 5–7 days before elective surgery: Conservative practice given the theoretical antiplatelet activity; mirrors guidance for fish oil and other Nrf2-modulating supplements.

Therapeutic Protocol

The standard protocol used by clinicians and researchers working with sulforaphane targets a daily dose of approximately 50–100 μmol of bioavailable sulforaphane (roughly 9–18 mg of free sulforaphane). This range reflects the levels used in successful biomarker-modulating human trials.

  • Dietary approach: 30–60 grams of fresh broccoli sprouts (3–5 days old) per day, lightly chewed or briefly blended, consumed within 30 minutes of preparation to preserve myrosinase activity. Approximate yield: 60–150 μmol sulforaphane depending on cultivar and growing conditions. This is the approach most strongly advocated by Rhonda Patrick (FoundMyFitness).

  • Supplement approach: Glucoraphanin paired with active myrosinase (e.g., Avmacol, Sulforaclear, BroccoMax with myrosinase, Prostaphane) at doses of 100–200 mg glucoraphanin per day, ideally with confirmed in-vitro sulforaphane yield. This is the approach most often used in clinical trials and recommended by Chris Kresser and Life Extension.

  • Combined approach (used in some Johns Hopkins and Texas Tech protocols): Stabilized sulforaphane preparations or combination of sprouts plus glucoraphanin-myrosinase capsules; favored in older adults or those with reduced gut myrosinase-converting bacteria.

Competing approaches exist regarding source. Some practitioners prefer whole-food sprouts as more “complete” (sulforaphane is one of many beneficial isothiocyanates and polyphenols in sprouts). Others favor standardized supplements for dose consistency and food-safety concerns. No head-to-head outcome trials definitively favor one approach over the other; biomarker studies suggest comparable Nrf2 induction when total bioavailable sulforaphane is matched.

  • Best time of day: Most practitioners recommend morning dosing on an empty or light-stomach context to maximize absorption. Some clinicians split the dose (morning and afternoon) to maintain steady-state exposure given the 1.8–2.0 hour plasma half-life.

  • Half-life: Plasma half-life of approximately 1.8–2.0 hours; the downstream Nrf2-induced enzyme upregulation persists 24–72 hours, supporting once-daily dosing for most indications despite short plasma residence.

  • Single vs. split dose: Single morning dose is most common in published trials and consumer protocols; some clinicians split into two daily doses to maintain steadier plasma levels, particularly for inflammatory or psychiatric indications.

  • Genetic considerations: GSTM1/GSTT1 null individuals may benefit from lower or split dosing given altered clearance kinetics. APOE4 (apolipoprotein E ε4 — a gene variant associated with increased Alzheimer’s disease risk) carriers are sometimes targeted for higher-dose neuroprotective protocols, though no genotype-stratified trial has confirmed this.

  • Sex-based differences: No established sex-specific dose adjustments; women may experience slightly more pronounced effects on hormone-sensitive tissues, but this has not produced specific dosing guidance.

  • Age-related considerations: Older adults (65+) may have reduced gut myrosinase-converting microbiota and benefit from formulations with active plant myrosinase rather than glucoraphanin-only products. Doses are typically not reduced in older adults absent specific tolerability concerns.

  • Baseline biomarker considerations: Patients with elevated hs-CRP, oxidized LDL, or markers of oxidative stress are typical responders; baseline thyroid panel and iodine status should be confirmed before chronic high-dose use.

  • Pre-existing condition considerations: Hypothyroidism (additional iodine and TSH monitoring), inflammatory bowel disease (start lower and slower), and active malignancy under treatment (coordinate with oncology team given ongoing trials) require individualized adjustments.

Discontinuation & Cycling

  • Lifelong vs. short-term: Sulforaphane is generally used as an ongoing dietary or supplemental intervention rather than a short-course therapy. Most longevity-oriented protocols treat it as indefinite once tolerated, similar to dietary cruciferous intake. Disease-specific protocols (e.g., autism, schizophrenia trials) typically involve fixed durations of 12–18 weeks but do not specify a discontinuation requirement.

  • Withdrawal effects: No physiological dependence or withdrawal syndrome has been described. Stopping use returns Nrf2-induced enzyme expression to baseline over approximately 1–2 weeks.

  • Tapering protocol: Tapering is not required. The compound can be discontinued abruptly without rebound effects.

  • Cycling: No clear evidence supports or refutes cycling. Some practitioners cycle (e.g., 5 days on, 2 days off) on the theory of preserving Nrf2 sensitivity, but no controlled human studies have demonstrated either benefit from cycling or tachyphylaxis (diminishing response over time) from continuous use. Most published protocols use continuous daily dosing.

Sourcing and Quality

  • Source forms: Sulforaphane reaches the user in three principal forms — (1) fresh sprouts, (2) glucoraphanin-only supplements, (3) glucoraphanin + active myrosinase supplements (or stabilized sulforaphane). Each has distinct quality considerations.

  • What to look for in supplements: Active myrosinase content is the single most important specification — without it, glucoraphanin-only supplements rely entirely on gut microbial conversion, which is highly variable. Look for product labels that specify total sulforaphane yield (in μmol or mg), not just glucoraphanin content. Third-party testing (NSF, USP, ConsumerLab, or independent COA) confirms label accuracy and screens for heavy metals and microbial contamination.

  • Reputable products and brands: Avmacol and Avmacol Extra Strength (used in NIH-funded Johns Hopkins, Rochester, and Texas Tech trials); Prostaphane (used in French prostate cancer studies); BROQ; Sulforaclear by Metagenics; Optimized Broccoli with Myrosinase (Life Extension); BrocElite (referenced by Chris Kresser). Each has documented in-vivo sulforaphane production data.

  • Sprout sourcing: Reputable brands of broccoli seeds for home sprouting include those tested for E. coli and Salmonella. Commercial fresh sprouts from refrigerated displays at reputable grocers should bear date labels and be consumed within several days.

  • Cooking considerations: Mature broccoli’s sulforaphane yield can be partially preserved by light steaming (1–3 minutes) and improved by adding a small amount of mustard powder (which contains active myrosinase) to cooked broccoli — increases yield approximately 4-fold.

Practical Considerations

  • Time to effect: Acute Nrf2-target gene induction is detectable in peripheral blood within 24 hours of a single dose. Phase II detoxification enzyme upregulation reaches steady state in 1–2 weeks. Inflammatory biomarker changes (hs-CRP, IL-6) typically require 4–8 weeks. Lipid effects appear at 8–12 weeks. Cancer-relevant tissue biomarker changes (Ki-67) require 6–12 months in trials. Subjective effects, when reported, are typically described in the first 2–4 weeks.

  • Common pitfalls: (1) Using glucoraphanin-only supplements without active myrosinase, producing low and inconsistent sulforaphane yield. (2) Cooking broccoli to the point of inactivating myrosinase without compensating with mustard powder or sprouts. (3) Storing fresh sprouts for too long after harvest, allowing sulforaphane to degrade. (4) Sourcing raw sprouts from unverified suppliers, raising foodborne illness risk. (5) Using doses substantially below the 50–100 μmol/day target seen in successful trials.

  • Regulatory status: Sulforaphane and glucoraphanin are sold as dietary supplements in the United States and most jurisdictions. Not approved by the FDA for any disease indication. Off-label use by clinicians is common but not formally regulated. Avmacol and similar products are generally recognized as safe (GRAS) as foods or food ingredients.

  • Cost and accessibility: Pasteurized supplement products generally cost $30–70 per month at therapeutic doses. Home sprouting (broccoli seeds plus a sprouting jar) yields equivalent dosing at a fraction of the cost — under $5 per month — but requires preparation labor and food-safety vigilance. Fresh commercial sprouts are intermediate in cost (~$3–6 per package, several packages per week).

Interaction with Foundational Habits

  • Sleep: Indirect potentiating interaction. No direct evidence that sulforaphane improves sleep quality, but reduction of systemic inflammation may secondarily benefit sleep architecture in those with high baseline inflammation. No reports of sulforaphane disrupting sleep at any dose. Practical consideration: morning dosing avoids any theoretical alertness-related concerns.

  • Nutrition: Direct potentiating interaction. Sulforaphane works synergistically with broader cruciferous vegetable intake, mustard family vegetables (which provide additional myrosinase), and dietary patterns rich in polyphenols (Mediterranean, DASH — Dietary Approaches to Stop Hypertension, MIND — Mediterranean-DASH Intervention for Neurodegenerative Delay diet). Iodine-replete nutrition is especially important to mitigate goitrogenic potential. Some evidence suggests fat in the meal modestly improves absorption.

  • Exercise: Direct potentiating interaction. Both exercise and sulforaphane activate Nrf2 — they are partially redundant pathways. Some preclinical work suggests sulforaphane can preserve exercise-induced muscle adaptations and reduce post-exercise oxidative stress; the ongoing NCT07343518 athletic-performance trial is testing this. No evidence that sulforaphane blunts hypertrophy or training adaptations. Timing relative to workouts has not been systematically studied.

  • Stress management: Indirect interaction. Chronic psychological stress drives oxidative stress and inflammation through cortisol-mediated and cytokine-mediated pathways; sulforaphane addresses downstream consequences but does not modulate cortisol directly. No specific dose-timing interaction with stress management practices has been described.

Monitoring Protocol & Defining Success

Baseline testing before initiating chronic sulforaphane use is recommended primarily to assess thyroid status, oxidative stress markers, and lipid profile, which together establish the response framework and the practical safety floor.

Biomarker Optimal Functional Range Why Measure It? Context/Notes
TSH 0.5–2.5 mIU/L Detects thyroid stress; baseline for goitrogen monitoring TSH = thyroid stimulating hormone. Conventional reference: 0.4–4.5 mIU/L; functional medicine targets are tighter
Free T4 1.0–1.5 ng/dL Confirms adequate thyroid hormone production Pair with TSH
Urinary iodine 100–199 μg/L (population median target) Identifies deficiency that elevates goitrogenic risk Spot test; multiple samples for accuracy
hs-CRP < 1.0 mg/L Marker of systemic inflammation; primary response biomarker hs-CRP = high-sensitivity C-reactive protein. Fasting preferred; avoid testing during acute illness
Total cholesterol 150–200 mg/dL Cardiometabolic baseline Fasting required
LDL-C < 100 mg/dL (functional: < 80 mg/dL) Tracks lipid response LDL-C = low-density lipoprotein cholesterol. Fasting required; calculated or directly measured
Triglycerides < 100 mg/dL Tracks lipid response Fasting required
HbA1c 4.6–5.4% Glycemic baseline HbA1c = glycated hemoglobin, a 3-month average blood-sugar marker. Non-fasting acceptable
Fasting glucose 70–90 mg/dL Glycemic baseline Fasting required
Comprehensive Metabolic Panel Standard ranges Renal and hepatic baseline Includes creatinine, eGFR (estimated glomerular filtration rate — kidney filtering capacity), liver enzymes

Ongoing monitoring follows a cadence of baseline, 8–12 weeks after initiation, then every 6–12 months thereafter, focusing on lipid panel, hs-CRP, and TSH. For users on chronic high-dose protocols (>100 μmol/day equivalent), an additional 6-month TSH check is prudent.

Qualitative markers complementing the lab panel include:

  • Subjective energy and post-meal alertness
  • Frequency and severity of seasonal/environmental allergic responses
  • Skin appearance, particularly in those with rosacea or eczema
  • Cognitive clarity and processing speed (self-reported)
  • Recovery time from intense exercise
  • Frequency of upper respiratory infections through cold-and-flu seasons

Emerging Research

  • Age-Associated Cardiac and Vascular Function Trial: NCT05408559 — Texas Tech University Health Sciences Center, Phase 1/2, recruiting, 200 participants. Testing whether 24 weeks of Avmacol Extra Strength can attenuate age-associated cardiac and vascular dysfunction with echocardiography, exercise endurance, and PBMC (peripheral blood mononuclear cell) mitochondrial function as endpoints. The most directly longevity-relevant ongoing trial.

  • DROPS Trial — Decreasing Risk of Psychosis by Sulforaphane: NCT03932136 — Shanghai Jiao Tong University, Phase 3, recruiting, 300 clinical-high-risk individuals. Primary endpoint: 2-year conversion rate to psychosis. The largest and longest-duration sulforaphane psychiatric trial.

  • Sulforaphane in Chronic Kidney Disease (Avmacol ES): NCT05797506 — University of Rochester, Phase 2, active, 100 participants (CKD stages 3–4). Testing whether daily sulforaphane slows kidney disease progression via reduction of oxidative stress and inflammation.

  • Melanoma Prevention in Atypical Mole Patients: NCT07040280 — Eastern Cooperative Oncology Group, Phase 2, 120 participants, starting 2025. Testing 12 months of broccoli sprout extract for effects on atypical mole evolution and melanoma risk.

  • Sulforaphane Cardioprotection during Doxorubicin Chemotherapy: NCT03934905 — Texas Tech, Phase 1/2, recruiting, 70 breast cancer patients. Testing whether sulforaphane can protect against anthracycline-induced cardiomyopathy without compromising tumor response.

  • Sulforaphane in ADHD: NCT06594536 — Assistance Publique - Hôpitaux de Paris, 70 children. Tests sulforaphane efficacy in attention deficit hyperactivity disorder; first major French pediatric trial outside autism.

  • Bioavailability research direction: Multiple groups continue work on oral formulations that bypass gut myrosinase variability. The University of Exeter probiotic-myrosinase study (NCT06561893) is testing whether oral L. plantarum can reliably convert glucoraphanin to sulforaphane in humans regardless of native microbiome composition.

  • Counter-evidence direction: The 2023 Czech pediatric autism trial (Magner et al., 2023) found no significant clinical improvement in young children with autism, contrasting with the original Singh adolescent/adult finding. The accumulating null pediatric evidence may narrow rather than expand the range of validated sulforaphane indications.

  • Methodological concern direction: Growing recognition that “glucoraphanin dose” and “sulforaphane dose” are not interchangeable across formulations is prompting investigators to standardize urinary mercapturic acid excretion as a pharmacokinetic confirmation in trials. This may resolve some of the heterogeneity noted in existing systematic reviews (ElKhalifa et al., 2023).

Conclusion

Sulforaphane is a sulfur-containing compound formed in cruciferous vegetables — most abundantly young broccoli sprouts — that activates a master cellular defense pathway, prompting the body to produce its own antioxidant, detoxification, and anti-inflammatory enzymes. For health- and longevity-oriented adults, the most consistently demonstrated human effects are stronger built-in detoxification activity, increased excretion of common environmental toxins, and modest improvements in lipid profile and inflammatory markers. Evidence for benefits in autism, schizophrenia, kidney disease, and cancer prevention is more variable — promising in some indications, conflicted in others, and still preclinical for most aging-related endpoints. The principal practical considerations are bioavailability variability across product forms, the goitrogenic potential at chronic high doses without adequate iodine, mild and dose-related gastrointestinal effects, and the foodborne illness risk of raw home-grown sprouts. The evidence base is substantial but uneven: strong on mechanism and biomarker endpoints, less consolidated on hard clinical outcomes. A notable conflict-of-interest consideration is that several pivotal studies and named branded products carry direct commercial sponsorship by their manufacturers, which shapes both product visibility and the design of clinical evidence. Dosing and source choices materially affect what is actually delivered to the body, leaving formulation literacy as a determining factor in real-world response.

Top - Benefits - Risks - Protocol